05:54 PM EDT, 03/25/2024 (MT Newswires) -- Eledon Pharmaceuticals ( ELDN ) said late Monday the 12th participant has been enrolled in an ongoing phase 2 trial evaluating its lead investigational product tegoprubart head-to-head with tacrolimus to prevent organ rejection in kidney transplantation.

Organ rejection is a major cause of graft failure in transplantation procedures, according to the company.

Eledon shares were up 3.9% in after-hours activity.

Price: 2.15, Change: +0.08, Percent Change: +3.86